0001193125-26-212075
SEC filingQ1 FY2026 delivered zero revenue and gross profit following the FYARRO Divestiture, driving operating loss to -$23.5M and net loss to -$22.2M, versus prior-year profit from the divestiture gain.
Q1 FY2026 revenue and gross profit both registered at $0, representing a 100% year-over-year decline from $7.1M and $6.4M respectively. This complete elimination traces directly to the FYARRO Divestiture, which closed on March 25, 2025, transferring commercialization rights and operations to KAKEN. Management's MD&A explicitly attributes the decrease in cost of goods sold to this transaction, removing the company's prior sole revenue source from advanced malignant PEComa treatment. The strategic shift refocuses Whitehawk as a clinical-stage biotech, prioritizing ADC Therapies pipeline development over commercial infrastructure maintenance.
Operating income deteriorated to -$23.5M, a 54.6% widening from -$15.2M in Q1 FY2025. Without FYARRO sales to offset expenses, the business absorbed full R&D and overhead costs during this transitional quarter. The divestiture's closure late in the prior period means Q1 FY2026 captures a clean post-commercial baseline, highlighting the capital-intensive nature of advancing product candidates. Investors should note this positions the company for pipeline milestones, though it underscores ongoing unprofitability absent revenue.